Paolo Pozzilli Selected Research

otelixizumab

1/2016	Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
10/2014	Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
1/2011	Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paolo Pozzilli Research Topics

Disease

63	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2022 - 03/2002
36	Type 2 Diabetes Mellitus (MODY) 10/2022 - 03/2002
13	Insulin Resistance 10/2022 - 03/2002
10	Latent Autoimmune Diabetes in Adults 06/2018 - 03/2008
6	Diabetes Complications 10/2022 - 01/2004
6	Body Weight (Weight, Body) 04/2021 - 03/2002
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 08/2013
6	Inflammation (Inflammations) 11/2020 - 03/2014
5	COVID-19 01/2022 - 01/2020
5	Diabetes Mellitus 01/2022 - 12/2012
5	Obesity 01/2021 - 03/2007
5	Hypoglycemia (Reactive Hypoglycemia) 12/2017 - 01/2004
4	Overweight 01/2021 - 03/2014
4	Hyperglycemia 01/2015 - 05/2006
3	Hypertension (High Blood Pressure) 01/2022 - 03/2014
3	Bone Resorption 01/2018 - 01/2016
3	Insulinoma 04/2014 - 04/2002
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2013 - 01/2009
2	Fatty Liver 01/2022 - 07/2011
2	Chronic Disease (Chronic Diseases) 01/2022 - 01/2011
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 04/2021 - 12/2017
2	Thyroid Nodule (Nodule, Thyroid) 01/2021 - 01/2020
2	Frailty 11/2020 - 02/2016
2	Atrial Fibrillation 01/2020 - 05/2018
2	Neoplasms (Cancer) 10/2019 - 11/2008
2	Myocardial Infarction 01/2019 - 01/2015
2	Rheumatoid Arthritis 01/2017 - 07/2013
2	Autoimmune Diseases (Autoimmune Disease) 06/2013 - 03/2008
2	Hyperthyroidism 08/2011 - 12/2010
1	Disease Progression 10/2022
1	Left Ventricular Dysfunction 05/2022
1	Heart Failure 05/2022
1	Asthma (Bronchial Asthma) 01/2022
1	Albuminuria 01/2022
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	Morbid Obesity 01/2022

Drug/Important Bio-Agent (IBA)

41	Insulin (Novolin)FDA Link 10/2022 - 07/2002
20	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2005
16	AutoantibodiesIBA 01/2019 - 07/2002
14	C-PeptideIBA 10/2022 - 07/2002
10	AntigensIBA 01/2020 - 04/2002
8	Biomarkers (Surrogate Marker)IBA 10/2022 - 02/2013
8	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2009
8	AntibodiesIBA 01/2019 - 03/2008
6	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2018 - 01/2009
5	Hormones (Hormone)IBA 01/2021 - 12/2010
4	LipidsIBA 11/2020 - 01/2014
4	AutoantigensIBA 01/2020 - 02/2012
4	CytokinesIBA 01/2020 - 11/2008
4	dulaglutideIBA 12/2019 - 01/2017
4	Vitamin D FDA LinkGeneric 11/2016 - 09/2010
3	Advanced Glycation End ProductsIBA 01/2021 - 11/2004
3	Calcitriol (Calcijex)FDA LinkGeneric 01/2020 - 09/2010
3	LDL CholesterolIBA 01/2019 - 01/2014
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2018 - 06/2003
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 12/2017 - 02/2012
3	Hypoglycemic Agents (Hypoglycemics)IBA 11/2017 - 06/2012
3	EnzymesIBA 06/2017 - 07/2011
3	otelixizumabIBA 01/2016 - 01/2011
2	Sodium-Glucose Transporter 2 InhibitorsIBA 05/2022 - 11/2020
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 01/2018
2	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021 - 11/2020
2	Antihypertensive Agents (Antihypertensives)IBA 11/2020 - 06/2018
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 11/2020 - 01/2020
2	CalciumIBA 01/2020 - 11/2016
2	Growth Hormone (Somatotropin)IBA 10/2019 - 05/2003
2	oxidized low density lipoproteinIBA 01/2019 - 01/2014
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 10/2018
2	Parathyroid Hormone (Parathormone)IBA 01/2018 - 11/2016
2	ThiazolidinedionesIBA 01/2018 - 03/2002
2	Collagen Type I (Type I Collagen)IBA 01/2018 - 01/2017
2	Metformin (Glucophage)FDA LinkGeneric 01/2018 - 01/2017
2	ChemokinesIBA 11/2016 - 05/2012
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 11/2016 - 06/2013
2	AdipokinesIBA 01/2016 - 02/2013
2	Proton Pump InhibitorsIBA 10/2015 - 11/2013
2	OsteocalcinIBA 07/2014 - 01/2013
2	Glucagon (Glukagon)FDA Link 01/2014 - 10/2008
2	CholesterolIBA 01/2014 - 07/2011
2	Interleukin-13IBA 05/2012 - 06/2003
2	Protein Tyrosine PhosphatasesIBA 06/2008 - 03/2008
1	2'- ((4'- trifluoromethanesulfonyloxy)phenyl)- N- methanesulfonylpropionamideIBA 01/2022
1	Olive OilIBA 01/2022
1	Tadalafil (Cialis)FDA Link 01/2022
1	KetonesIBA 01/2022
1	Interleukin-8 ReceptorsIBA 01/2022
1	SphingolipidsIBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	Palm OilIBA 01/2022
1	Chemokine ReceptorsIBA 01/2022

Therapy/Procedure

42	Therapeutics 10/2022 - 07/2002
10	Glycemic Control 01/2019 - 01/2004
4	Immunotherapy 05/2015 - 05/2009
2	Mediterranean Diet 01/2021 - 11/2017
2	Laser Therapy (Surgery, Laser) 01/2021 - 01/2020
2	Radiofrequency Ablation 01/2021 - 01/2020
2	Catheter Ablation 01/2020 - 05/2018
2	Percutaneous Coronary Intervention 11/2019 - 01/2015
2	Injections 12/2017 - 01/2016
1	Bariatric Surgery 01/2022